| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
|
Poggio, F.
|
|
|
33 |
3 |
p. 347-349
|
article
|
| 2 |
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Powles, T.
|
|
|
33 |
3 |
p. 244-258
|
article
|
| 3 |
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape
|
D’souza, Anishka A.
|
|
|
33 |
3 |
p. 242-243
|
article
|
| 4 |
Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer
|
Di Noia, V.
|
|
|
33 |
3 |
p. 350-352
|
article
|
| 5 |
Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”
|
Gao, J.J.
|
|
|
33 |
3 |
p. 356
|
article
|
| 6 |
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
|
Nitz, U.A.
|
|
|
33 |
3 |
p. 355
|
article
|
| 7 |
COVID-19 vaccination and breakthrough infections in patients with cancer
|
Schmidt, A.L.
|
|
|
33 |
3 |
p. 340-346
|
article
|
| 8 |
Editorial Board
|
|
|
|
33 |
3 |
p. iii
|
article
|
| 9 |
European cancer mortality predictions for the year 2022 with focus on ovarian cancer
|
Dalmartello, M.
|
|
|
33 |
3 |
p. 330-339
|
article
|
| 10 |
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
|
Vergote, I.
|
|
|
33 |
3 |
p. 276-287
|
article
|
| 11 |
Homologous recombination deficiency testing in first-line ovarian cancer
|
Moore, K.N.
|
|
|
33 |
3 |
p. 231-233
|
article
|
| 12 |
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
|
Hayden, P.J.
|
|
|
33 |
3 |
p. 259-275
|
article
|
| 13 |
Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial
|
Lopes Cardozo, J.M.N.
|
|
|
33 |
3 |
p. 310-320
|
article
|
| 14 |
Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus
|
Ducreux, M.
|
|
|
33 |
3 |
p. 349-350
|
article
|
| 15 |
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
|
Tarantino, P.
|
|
|
33 |
3 |
p. 234-238
|
article
|
| 16 |
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
|
Nelli, F.
|
|
|
33 |
3 |
p. 352-354
|
article
|
| 17 |
Table of Contents
|
|
|
|
33 |
3 |
p. i-ii
|
article
|
| 18 |
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma ☆
|
Horwitz, S.
|
|
|
33 |
3 |
p. 288-298
|
article
|
| 19 |
The upper ECHELON against T-cell lymphoma
|
Bachy, E.
|
|
|
33 |
3 |
p. 239-241
|
article
|
| 20 |
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
|
Curigliano, G.
|
|
|
33 |
3 |
p. 321-329
|
article
|
| 21 |
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial
|
Han, H.S.
|
|
|
33 |
3 |
p. 299-309
|
article
|
Journal description